Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma

BACKGROUND: Circulating tumor (ct) DNA assays performed in clinical laboratories provide tumor biomarker testing support for biopharmaceutical clinical trials. Yet it is neither practical nor economically feasible for many of these clinical laboratories to internally develop their own liquid biopsy...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Suman, Moore, Mathew W., Ringler, Rebecca, Ghosal, Abhisek, Horvath, Kyle, Naef, Theodore, Anvari, Sheri, Cotter, Philip D., Gunn, Shelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528227/
https://www.ncbi.nlm.nih.gov/pubmed/33004033
http://dx.doi.org/10.1186/s12885-020-07445-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528227/
https://www.ncbi.nlm.nih.gov/pubmed/33004033
http://dx.doi.org/10.1186/s12885-020-07445-5

Ejemplares similares